MPLT
MapLight Reports Q3 2026 Financials and Outlines Plans for Confirmatory Phase 3 Trial
MapLight Therapeutics ended the quarter with $463.4 million in cash and announced initiation of ZEPHYR-2, a Phase 3 schizophrenia trial topline results of which are expected in late 2027, alongside ongoing enrollment for ADP studies.